This invention describes peptide-based agents which bind the SARS-CoV-2 virus with high affinity and specificity. Such agents can be used for the development of tests for coronavirus detection, as well as for therapeutics which can block or inhibit viral infection.
Currently, antibodies are the most widely used agents which bind SARS-CoV-2 with high affinity and specifically. The limitations and drawbacks for antibodies are cost, time for development and chemical stability, making their use difficult. However, peptide-based agents in this invention are smaller, less complex molecules which are less expensive to produce and develop. Additionally, they are generally more chemically stable than antibodies, and better suited for further modifications such as in conjugation reactions.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"
